Trial Profile
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in AcroMegaly - Endocrine cardiomyophaty: Response to cyclic GMP PDE5 inhibitors in Acromegaly cardiomyopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 10 May 2023 Status changed from recruiting to completed.
- 10 Jan 2018 New trial record